Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection

[1]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] , 1993 .

[2]  E. Anaissie,et al.  Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. , 1993, Blood.

[4]  F. Takaku,et al.  Effect of granulocyte colony‐stimulating factor on neutropenia due to chemotherapy for non‐Hodgkin's lymphoma , 1990, Cancer.

[5]  J. Gutterman,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.

[6]  S. Thongprasert,et al.  Systemic candidiasis in cancer patients. , 1984, The American journal of medicine.

[7]  A. Schaffner,et al.  Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. , 1982, The Journal of clinical investigation.

[8]  G. Bodey.  Fungal infections complicating acute leukemia. , 1966, Journal of chronic diseases.

[9]  E. Hersh,et al.  Pulmonary complications of acute leukemia , 1966, Cancer.